ROCKLATAN (latanoprost)
Rocklatan is a fixed-dose combination ophthalmic solution consisting of netarsudil (a Rho kinase inhibitor) and latanoprost (a prostaglandin F2α analogue). It is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By effectively lowering IOP, Rocklatan mitigates a primary risk factor for glaucomatous optic nerve damage and subsequent visual field loss.
How ROCKLATAN Works
Rocklatan reduces intraocular pressure by utilizing two distinct mechanisms to increase the outflow of aqueous humor. Netarsudil, a Rho kinase inhibitor, is believed to increase outflow primarily through the trabecular meshwork (the conventional pathway). Latanoprost, a prostaglandin F2α analogue, increases outflow primarily through the uveoscleral pathway (the unconventional pathway). Together, these components provide a dual-action approach to IOP reduction.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2019-03-12
- Patent Cliff
- 2034
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
ROCKLATAN Approval History
What ROCKLATAN Treats
2 indicationsROCKLATAN is approved for 2 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Open-Angle Glaucoma
- Ocular Hypertension
ROCKLATAN Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in ROCKLATAN's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications ROCKLATAN treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to ROCKLATAN
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
24 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02390284 STOP-RGCD results posted | 20140587 R01EY014957 | Ph 3 | terminated | Stop Retinal Ganglion Cell Dysfunction Study |
| NCT06666855 | 0117B02CN | Ph 3 | active not recruiting | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China |
| NCT00934089 results posted | A0191002 | Ph 2 | completed | A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 |
| NCT00716859 results posted | A6111137 | Ph 3 | completed | A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma. |
| NCT00638742 | A6111139 | Ph 1 | completed | A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost. |
| NCT00846989 | CRKI983A2201 | Ph 1, Ph 2 | completed | Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension |
| NCT03419975 | TJO-002-301 | Ph 3 | completed | A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients |
| NCT03966560 | KAEK-2014/04-74 | Ph 4 | completed | Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma |
| NCT01223378 Voyager results posted | 659 | Ph 2 | completed | Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension |
| NCT02622334 | BP30002 | Ph 1 | completed | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). |
| NCT01917383 | IPC-01-2013 | Ph 2 | completed | A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma |
| NCT01315574 BAK results posted | 11-007H | Ph 4 | terminated | Effects of Anti-Glaucoma Medications on the Ocular Surface |
| NCT01254370 | NVG10E118 | Ph 2 | completed | Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease |
| NCT02531152 | TDR13459 U1111-1153-3544 | Ph 1 | completed | 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension |
| NCT02083289 | ONO-9054IOU003 | Ph 2 | completed | A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG) |
| NCT00705757 results posted | Pfizer GA6111AX | Ph 4 | completed | The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye |
| NCT00941525 CCT-IOP | 83155 EudraCT: 2008-004629-41 | Ph 4 | completed | Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure |
| NCT01225653 Latano-2 | Latano-2 2010-022433-29 | Ph 4 | completed | Topical Application of Latanoprost in Diabetic Retinopathy |
| NCT01721707 | BRINZLAT-12 08233812.4.0000.5505 | Ph 3 | withdrawn | Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH |
| NCT01180062 Latanoprost SR | 10-0476-F1V IND# 109,182 | Ph 1 | terminated | Safety Study of Latanoprost Slow Release Insert |
| NCT01896180 | ALZ-1101-101 | Ph 2 | completed | Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost |
| NCT01410188 | OPA-6566-101 | Ph 1, Ph 2 | completed | Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension |
| NCT00821002 | PPL GLAU 05 | Ph 2 | completed | A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS) |
| NCT01151904 results posted | MA-COM004 | Ph 4 | terminated | Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ROCKLATAN FDA Label Details
Indications & Usage
FDA Label (PDF)ROCKLATAN is indicated for the treatment of Open-Angle Glaucoma; Ocular Hypertension.
ROCKLATAN Patents & Exclusivity
Patents (17 active)
Pro Intelligence Preview
Deep insights for ROCKLATAN
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2034
- • 17 active patents
Trial Analysis
- • 25 total trials
- • Stage: Declining
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment